Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis

Ruxolitinib has proven itself a stellar moneymaker for Incyte and Novartis, and it should come as no surprise that the drug’s efficacy reached expectations in yet another Phase III trial.